Erosion-free rheumatoid arthritis: clinical and conceptional implications—a BARFOT study

BMC Rheumatology

Table 4 Multiple logistic regression analysis of the associations between baseline variables and erosion-free disease up to 8 years. The model includes anti- CCP. 50% of the study patients were included in the model. Nagelkerke pseudo-R² was 0.30

	B	Wald	Sig	Exp(B)	95% C.I.for EXP(B)
	B	Wald	Sig	Exp(B)	Lower	Upper
Anti- CCP	− 1.752	25.631	.000	.173	.088	.342
Number of ACR-criteria	−.411	3.335	.068	.663	.427	1.031
Inclusion age	−.015	1.955	.162	.985	.965	1.006
Disease duration, months	.087	2.814	.093	1.091	.985	1.208
Current smoking	.378	1.246	.264	1.459	.751	2.834
DAS28	.040	.021	.884	1.041	.611	1.773
SJC28	−.056	2.589	.108	.946	.884	1.012
TJC28	.039	.947	.331	1.040	.961	1.124
ESR	−.003	.057	.811	.997	.977	1.018
Treatment start	.020	.006	.940	1.021	.601	1.734
Constant	2.072	2.329	.127	7.941

CI; confidence interval, Anti- CCP: anti-cyclic citrullinated protein, ACR: American College of Rheumatology, DAS28: 28-joints Disease Activity Score, SJC: swollen joint count, TJC: tender joint count, ESR: erythrocyte sedimentation rate, Treatment start: DMARDs and/or Prednisolone at study start (first visit or 3 months visit)

ISSN: 2520-1026